Relationship between High Sensitivity C-Reactive Protein Levels and the Severity of Vulgaris Psoriasis
DOI:
https://doi.org/10.37287/ijghr.v8i3.1105Keywords:
high-sensitivity c-reactive protein, inflammation, psoriasis area and severity index, psoriasis vulgaris, systemic inflammationAbstract
Psoriasis vulgaris is a chronic immune-mediated inflammatory skin disease increasingly recognized as a systemic inflammatory condition. High-sensitivity C-reactive protein (hs-CRP) is a sensitive marker of systemic inflammation, but its relationship with psoriasis severity remains inconsistent. This research evaluate the association between serum hs-CRP levels and disease severity in patients with psoriasis vulgaris. To evaluate the association between serum hs-CRP levels and disease severity in patients with psoriasis vulgaris. A cross-sectional analytical study was conducted involving 30 patients with psoriasis vulgaris and 30 control subjects at a tertiary hospital in Indonesia. Samples were obtained using non-probability sampling with a consecutive sampling technique, in which subjects who met the inclusion criteria were recruited sequentially until the minimum required sample size was achieved. Psoriasis severity was assessed using the Psoriasis Area and Severity Index (PASI). Serum hs-CRP levels were measured using enzyme-linked immunosorbent assay. Correlations between hs-CRP levels and PASI scores were analyzed using Spearman’s rank test. Most psoriasis patients had mild disease (56.7%). The mean serum hs-CRP level in the psoriasis group was 1.23 mg/L. No significant correlation was found between hs-CRP levels and PASI scores (r = 0.128, p = 0.499) or categorical disease severity. Although hs-CRP levels were higher in psoriasis patients than controls, the difference was not statistically significant. Serum hs-CRP levels were not associated with clinical severity of psoriasis vulgaris, suggesting that hs-CRP reflects systemic inflammation rather than cutaneous disease severity alone.
References
Aksentijevich, M., Lateef, S. S., Anzenberg, P., Dey, A. K., & Mehta, N. N. (2020). Chronic inflammation, cardiometabolic diseases and effects of treatment: Psoriasis as a human model. Trends in Cardiovascular Medicine, 30(8), 472–478.
Al-Maliki, A. N. A., Adem, Ş., & Nayyef, H. A. (2022). The relationship of IL-17a, Vit-D levels and some biochemical markers with psoriasis and the effect of oral vitamin D supplementation on clinical amelioration of the disease. International Journal of Computational and Experimental Science and Engineering, 8(3), 59–64.
Alsamarai, A. M., & Alobaidii, A. H. A. (2021). Psoriasis is a systemic disease: A proposed approach for inflammation scale calculation. Our Dermatology Online, 12(4), 381–386.
Amedi, S. T., & Zangana, S. N. (2021). High sensitivity C-reactive protein in psoriasis: A marker of disease severity and cardiovascular risk. Annals of the Romanian Society for Cell Biology, 25(4), 11820–11827.
Baran, A., Nowowiejska, J., Krahel, J. A., Kaminski, T. W., Maciaszek, M., & Flisiak, I. (2020). Higher serum selenoprotein P level as a novel inductor of metabolic complications in psoriasis. International Journal of Molecular Sciences, 21(13), 4594.
Basha, M., Shehata, W., Gayed, I., & El Hagary, S. (2021). The value of calcium and high-sensitivity C-reactive protein serum levels in psoriatic patients. Menoufia Medical Journal, 34(1), 56.
Boutet, M. A., Nerviani, A., Gallo Afflitto, G., & Pitzalis, C. (2018). Role of the IL-23/IL-17 axis in psoriasis and psoriatic arthritis: The clinical importance of its divergence in skin and joints. International Journal of Molecular Sciences, 19(2), 530.
Carè, A., & Moretti, A. (2024). The International Society of Gender Medicine: An updated history of a long journey. Journal of Sex-and Gender-Specific Medicine, 10(1), 2–3.
Dewi, Y. P. (2018). C-reactive protein (CRP) vs high-sensitivity CRP (hs-CRP). Siloam Hospital Yogyakarta.
Dey, A. K., Teague, H. L., Adamstein, N. H., Rodante, J. A., Playford, M. P., Chen, M. Y., et al. (2021). Association of neutrophil-to-lymphocyte ratio with non-calcified coronary artery burden in psoriasis. Journal of Cardiovascular Computed Tomography, 15(4), 372–379.
Earlia, N., Yunita, C., Bulqiah, M., Tasrif, A. Y., & Maghfirah, K. (2023). Pengaruh pemberian platelet-rich plasma terhadap derajat keparahan psoriasis vulgaris. J Med Sci, 3(2), 88–96.
Eder, L., Chandran, V., Rosen, C. F., Cook, R., & Gladman, D. D. (2024). AB0402 higher levels of high-sensitivity CRP is associated with future development of psoriatic arthritis in psoriasis. Annals of the Rheumatic Diseases, 83, 1448–1449.
Elton, J. (2025). lncRNAs and miRNAs: Key regulators in the pathogenesis of cSCC, senescence, and psoriasis [Doctoral dissertation, Karolinska Institutet].
Gerbase, A. C., Lopes, N. T., & Zemouri, C. (2023). International public health strategies in dermatology. In Dermatology in public health environments: A comprehensive textbook (pp. 9–29). Springer.
Gerdes, S., Pinter, A., Papavassilis, C., & Reinhardt, M. (2020). Effects of secukinumab on metabolic and liver parameters in plaque psoriasis patients. Journal of the European Academy of Dermatology and Venereology, 34(3), 533–541.
Gu, X., Shen, H., Jiang, J., Gu, P., Liu, P., Zhao, Z., et al. (2025). Association of the monocyte-to-high density lipoprotein ratio with the FRS and as a predictor of cardiovascular risk in individuals with psoriasis vulgaris. Clinical, Cosmetic and Investigational Dermatology, 1051–1062.
Gupta, S., Garg, P., Gupta, N., & Gupta, N. (2019). High sensitivity C-reactive protein, a predictor of cardiovascular mortality and morbidity, and psoriasis. International Journal of Research in Dermatology, 5(2), 338.
Hanani, N. K., Ervianti, E., & Rahniayu, A. (2020). Clinical profile of psoriasis vulgaris at Soetomo General Hospital, Surabaya. Health Notions, 4(8), 282–289.
Houttekiet, C., de Vlam, K., Neerinckx, B., & Lories, R. (2022). Systematic review of the use of CRP in clinical trials for psoriatic arthritis. RMD Open, 8(1), e001756.
Indrajaya, T., Saleh, M. I., & Miliyandra, M. (2020). The role of high-sensitivity C-reactive protein serum in assessing troponin T in acute myocardial infarction. Open Access Macedonian Journal of Medical Sciences, 8(B), 1053–1056.
Jiang, Z., Jiang, X., Chen, A., & He, W. (2023). Platelet activation: A promoter for psoriasis and its comorbidity, cardiovascular disease. Frontiers in Immunology, 14, 1238647.
Jerab, D., Blangero, F., da Costa, P. C. T., de Brito Alves, J. L., Kefi, R., Jamoussi, H., et al. (2025). Beneficial effects of omega-3 fatty acids on obesity and related metabolic and chronic inflammatory diseases. Nutrients, 17(7), 1253.
Kaur, I., Gandhi, V., Raizada, A., Bhattacharya, S. N., Tripathi, A. K., & Jakhar, D. (2020). Psoriatic nephropathy and its correlation with hs-CRP. Indian Dermatology Online Journal, 11(1), 29–34.
Kurniawati, R., & Sugianto, P. (2021). Relationship between high sensitivity-C reactive protein level and impaired cognitive function in HIV patients. Folia Medica Indonesiana, 57(1), 63.
Lattarulo, S., Centrone, F., & Chironna, M. (2025). Anti-MDA5+ dermatomyositis following SARS-COV-2 infections: A systematic review. Frontiers in Immunology, 16.
Lecumberri, A., Berna-Rico, E., Gelfand, J. M., Svedbom, A., de Aragón, C. A. J., Neria, F., et al. (2025). Residual inflammation in patients with psoriasis treated with biologic therapy. Journal of Investigative Dermatology.
Lubis, H. H. (2023). Hubungan kadar high sensitivity C-reactive protein (hs-CRP) dengan derajat keparahan dermatitis atopik pada anak [Thesis, Universitas Sumatera Utara].
Magee, C., Jethwa, H., FitzGerald, O. M., & Jadon, D. R. (2021). Biomarkers predictive of treatment response in psoriasis and psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease, 13, 1759720X211014010.
Mannangi, N. B., Devaranavadagi, B., Jayaram, S., Ankad, B. S., & S. D. S. (2022). A study of inflammatory markers and their correlation with PASI score in psoriasis. Biomedicine (Taipei), 42(2), 230–235.
Megawati, G., Indraswari, N., Johansyah, A. A., Kezia, C., Herawati, D. M. D., Gurnida, D. A., et al. (2023). Comparison of hs-CRP in adult obesity and central obesity in Indonesia. International Journal of Environmental Research and Public Health, 20(18), 6734.
Mehrmal, S., Uppal, P., Nedley, N., Giesey, R. L., & Delost, G. R. (2021). The global, regional, and national burden of psoriasis. Journal of the American Academy of Dermatology, 84(1), 46–52.
Merzel Šabović, E. K., Kraner Šumenjak, T., Božič Mijovski, M., & Janić, M. (2025). Residual non-specific and disease-specific inflammatory markers in successfully treated young psoriasis patients. Immunologic Research, 73(1), 28.
Moeza, M. K., Nababan, K. A., & Yosi, A. (2023). Psoriasis profile at Adam Malik Hospital: A retrospective study. Medan.
Nguyen, H. T., Vo, L. D. H., & Pham, N. N. (2022). Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as inflammatory markers in psoriasis. Dermatology Reports, 15(1), 9516.
Niknezhad, N., Haghighatkhah, H. R., Zargari, O., Ghalamkarpour, F., Younespour, S., Niknejad, N., et al. (2020). High-sensitivity C-reactive protein as a biomarker in detecting subclinical atherosclerosis in psoriasis. Dermatologic Therapy, 33(4).
Paschoal, R. S., Silva, D. A., Cardili, R. N., & da Silva Souza, C. (2018). Metabolic syndrome, C-reactive protein and cardiovascular risk in psoriasis patients. Anais Brasileiros de Dermatologia, 93(2), 222–228.
Pokharel, R., Agrawal, S., Pandey, P., & Lamsal, M. (2022). Assessment of vitamin D level in patients with psoriasis and its correlation with disease severity. Psoriasis: Targets and Therapy, 12, 251–258.
Prakoeswa, C. R. S., Hidayati, A. N., Hendaria, M. P., Listiawan, M. Y., Utomo, B., Damayanti, D., et al. (2021). The profile of psoriasis vulgaris patients. Berkala Ilmu Kesehatan Kulit dan Kelamin, 33(3), 173.
Ramessur, R., Corbett, M., Marshall, D., Acencio, M. L., Barbosa, I. A., Dand, N., et al. (2022). Biomarkers of disease progression in people with psoriasis. British Journal of Dermatology, 187(4), 481–493.
Rendon, A., & Schäkel, K. (2019). Psoriasis pathogenesis and treatment. International Journal of Molecular Sciences, 20(6), 1475.
Segar, D., Praharsini, I., & Indira, I. E. (2019). Prevalence and clinical manifestations of patients with psoriasis in RSUP Sanglah. Intisari Sains Medis, 10(3).
Shofiyah, L., Ardyanto, T. D., Prabowo, N. A., Aprilningsih, H., Myrtha, R., Kuncorowati, N. D. A., et al. (2025). Role of gamma-glutamyl transferase, high sensitivity C reactive protein and apolipoprotein B as a marker of disease severity in psoriasis. Gema Lingkungan Kesehatan, 23(3), 377–383.
Sokolova, M. V., Simon, D., Nas, K., Zaiss, M. M., Luo, Y., Zhao, Y., et al. (2020). A set of serum markers detecting systemic inflammation in psoriatic disease. Arthritis Research & Therapy, 22(1), 26.
Tsiogka, A., Gregoriou, S., Stratigos, A., Soulaidopoulos, S., Rompoti, N., Panagakis, P., et al. (2023). The impact of treatment with IL-17/IL-23 inhibitors on subclinical atherosclerosis. Biomedicines, 11(2), 318.
Wang, H. N., & Huang, Y. H. (2020). Changes in metabolic parameters in psoriatic patients treated with secukinumab. Therapeutic Advances in Chronic Disease, 11, 2040622320944777.
Wirth, T., Balandraud, N., Boyer, L., Lafforgue, P., & Pham, T. (2022). Biomarkers in psoriatic arthritis. Frontiers in Immunology, 13.
Yang, H., & Zheng, J. (2020). Influence of stress on the development of psoriasis. Clinical and Experimental Dermatology, 45(3), 284–288.
Öztürk, G. S., Ergun, T., Eyüboğlu, İ. P., & Akkiprik, M. (2021). Serum high-sensitivity C-reactive protein and cytokine levels in hidradenitis suppurativa. Cytokine, 144, 155585.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Indonesian Journal of Global Health Research
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
